$-0.07
(Market cap
$9 Mln
Revenue (TTM)
$54 Mln
P/E Ratio
--
P/B Ratio
5.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-19.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-6.1
-
Debt to Equity
-1.9
-
Book Value
$--
-
EPS
$-60.1
-
Face value
--
-
Shares outstanding
813,132
10 Years Aggregate
CFO
$83.27 Mln
EBITDA
$90.21 Mln
Net Profit
$-173.72 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Trinity Biotech - ADR
| -59.2 | 5.8 | -52.5 | -78.2 | -84.7 | -75.1 | -57.4 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Trinity Biotech - ADR
| -96.4 | -58.8 | -56.6 | -30.8 | -62.5 | 268.7 | -54.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Trinity Biotech - ADR
|
9.7 | 8.6 | 43.8 | -37.4 | -33.5 | 69.8 | -- | 5.7 |
| 61.5 | 8,484.6 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.1 | |
| 14.5 | 9,638.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.7 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.3 | |
| 57.5 | 9,074.5 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 180.0 | 10,905.5 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 16.4 | |
| 100.5 | 6,525.3 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24 | 5.0 | |
| 321.8 | 12,752.7 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.4 | 8.4 | |
| 178.2 | 10,222.2 | 785.1 | 41.5 | 9.9 | 2 | 251.6 | 4.8 | |
| 28.9 | 12,153.4 | 6,164.0 | 625.0 | 13.0 | 11.8 | 19.9 | 2.4 |
Shareholding Pattern
View DetailsAbout Trinity Biotech - ADR
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and... Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. It has a strategic collaboration agreement with Echelon Data Centres to develop advanced liquid cooling solutions for AI infrastructure. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. Read more
-
President, CEO, Company Secretary & Director
Mr. John Gillard
-
President, CEO, Company Secretary & Director
Mr. John Gillard
-
Headquarters
Bray
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Trinity Biotech - ADR
What is the current share price of Trinity Biotech plc - ADR Today?
The share price of Trinity Biotech plc - ADR is $9.68 (NASDAQ) as of 28-Aug-2026 16:04 EDT. Trinity Biotech plc - ADR has given a return of -84.72% in the last 3 years.
What is the current PB & PE ratio of Trinity Biotech plc - ADR?
Since, TTM earnings of Trinity Biotech plc - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.01 |
-0.01 |
2024 |
-0.01 |
-0.01 |
2023 |
-0.16 |
-0.16 |
2022 |
-0.01 |
-0.12 |
2021 |
0.29 |
-0.78 |
What is the 52 Week High and Low of Trinity Biotech plc - ADR?
The 52-week high and low of Trinity Biotech plc - ADR are Rs 52.50 and Rs 7.94 as of 29-Aug-2026.
What is the market cap of Trinity Biotech plc - ADR?
Trinity Biotech plc - ADR has a market capitalisation of $ 9 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Trinity Biotech plc - ADR?
Before investing in Trinity Biotech plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.